No significant associations were observed between T-DXd efficacy and the median number of baseline tumor-infiltrating CD4+ (132.7 vs. 12.2 cells/mm2; P = 0.076), CD68+ (217.3 vs. 161.9 cells/mm2; P = 0.92), CD163+ (286.8 vs. 127.7 cells/mm2; P = 0.24), CD208+ (1.3 vs. 3.6 cells/mm2; P = 0.43), or CD1a+ (0 vs. 0.2 cells/mm2; P = 0.83) immune cells in responders versus nonresponders (Fig. 2C). This evidence concerns the gene CD163 and neoplasm.